Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

4170 - Patterns of venous thromboembolism risk in patients with localized colorectal cancer undergoing adjuvant chemotherapy or active surveillance


08 Oct 2016


Poster Display


Jakob Riedl


Annals of Oncology (2016) 27 (6): 149-206. 10.1093/annonc/mdw370


J. Riedl1, F. Posch1, M. Stotz1, A. Bezan1, T. Winder2, R. Schaberl-Moser1, M. Pichler1, H. Stoeger1, A. Gerger1

Author affiliations

  • 1 Clinical Division Of Medical Oncology, Department Of Internal Medicine, Medical University Graz, 8036 Graz - Graz/AT
  • 2 Medizinische Onkologie, Universitätsspital Zürich, 8091 - Zürich/CH


Abstract 4170


The risk of cancer-associated venous thromboembolism (VTE) is highly elevated in pts w/ metastatic colorectal cancer (CRC), and in particular during antineoplastic therapy. However, patterns of VTE risk in pts w/ localized CRC are unclear. Here, we estimate the risk of VTE in CRC pts after curative surgery, and define its association with baseline risk factors, adjuvant chemotherapy (adjCTX), disease recurrence, and death.


In this single-center historical cohort study, 562 pts w/ CRC (median age = 65.3 years; stages I, II, and III: n = 29, (5.2%), n = 160 (28.7%), n = 368 (66.1%); adjCTX: n = 346 (61.7%)) were included at the time of surgery and followed-up until the onset of VTE, disease recurrence, and death. The primary endpoint of this study was the cumulative incidence of objectively-confirmed, symptomatic or incidental deep vein thrombosis and/or pulmonary embolism (VTE), accounting for death as a competing risk.


During a median follow-up of 2.9 years, we observed 18 VTE events (3.2%), 142 recurrences (25.3%), and 52 pts (9.3%) died. The 6-month, 1-year, and 5-year risk of VTE was 1.4%, 1.8%, and 3.3%, respectively. In univariable time-to-VTE regression, adjCTX was not associated with an increased risk of VTE (Subdistribution hazard ratio = 1.03, 95%CI: 0.40-2.66, p = 0.95). In multi-state analysis, the onset of disease recurrence emerged to be associated w/ an excessive increase in the risk of VTE (Transition hazard ratio (THR) = 11.8, 95%CI: 4.02-35.81, p 


The risk of VTE in pts w/ localized CRC undergoing curative surgery is very low. Importantly, adjCTX does not appear to be a risk factor for VTE in this setting. Therefore, the role of primary thromboprophylaxis during adjCTX is likely of low clinical benefit. The by far strongest determinant of VTE risk in curatively treated CRC pts turned out to be disease recurrence. Conversely, VTE emerged as a risk factor for recurrence, which indicates that VTE can be an early clinical sign for recurrent disease in this patient population.

Clinical trial identification

Legal entity responsible for the study

Medical University of Graz


Medical University of Graz


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings